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Molecular diagnosis of patients with von Willebrand disease ispending in most populations due to the complexity and highcost of conventional molecular analyses. The need for molecu-
lar and clinical characterization of von Willebrand disease in Spain
prompted the creation of a multicenter project (PCM-EVW-ES) that
resulted in the largest prospective cohort study of patients with all types
of von Willebrand disease. Molecular analysis of relevant regions of the
VWF, including intronic and promoter regions, was achieved in the 556
individuals recruited via the development of a simple, innovative, rela-
tively low-cost protocol based on microfluidic technology and next-gen-
eration sequencing. A total of 704 variants (237 different) were identified
along VWF, 155 of which had not been previously recorded in the inter-
national mutation database. The potential pathogenic effect of these
variants was assessed by in silico analysis. Furthermore, four short tan-
dem repeats were analyzed in order to evaluate the ancestral origin of
recurrent mutations. The outcome of genetic analysis allowed for the
reclassification of 110 patients, identification of 37 asymptomatic carri-
ers (important for genetic counseling) and re-inclusion of 43 patients pre-
viously excluded by phenotyping results. In total, 480 patients were
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ABSTRACT
Introduction
Von Willebrand disease (VWD) is the most common
bleeding disorder, with a reported incidence of 0.01% to
1%.1,2 The condition is caused by abnormalities related to
the von Willebrand factor protein (VWF), which has an
important role in primary hemostasis.3,4 A diagnostic algo-
rithm based on the patient’s clinical history and the results
of laboratory testing to assess VWF levels and functionality
has enabled the classification of VWD into quantitative
(type 1 and type 3) and qualitative (type 2) abnormalities.1
The first-line tests used to classify VWD include the combi-
nation of VWF: antigen (Ag), VWF: ristocetin cofactor
(RCo), factor VIII:C (FVIII:C), and the VWF:RCo/VWF:Ag
ratio, whereas second-line tests include ristocetin-induced
platelet aggregation (RIPA), VWF:FVIIIB, VWF: collagen
binding (CB), VWF propeptide (pp), and multimer analysis,
which are especially useful to differentiate between the
type 2 VWD subtypes (2A, 2B, 2M, and 2N). It is essential
to correctly identify these subtypes because their treatment
differs. Nonetheless, this can be a challenging task as clini-
cal and laboratory phenotypes are very heterogeneous,5 and
some tests, such as RIPA and multimeric analysis, are not
available in all laboratories.6 Furthermore, there is often a
lack of clinical information, and the available laboratory
tests are known to have intrinsic limitations.1,7,8 In addition,
sequential application of these analyses makes phenotypic
VWD diagnosis increasingly more costly. 
The VWF glycoprotein is encoded by VWF gene, a large
(178 kb comprising 52 exons) and very polymorphic gene
(>100 coding single-nucleotide polymorphisms (cSNPs))
with a highly homologous partial pseudogene (VWFP;
exons 23-34),9 characteristics that make specific amplifica-
tion and sequencing of VWF difficult. Thus, molecular
analysis of VWF is a challenge. Although genetic analysis
is considered a valuable tool to support the diagnosis of
VWD,10,11 classic Sanger sequencing of the entire VWF is
too costly for general use in all patients. Hence, this
method has been applied, with slight variations, only to
specific exons of VWF, depending on the VWD subtype.
Exon 28 is sequenced for 2A, 2B, and 2M patients, and in
type 2A, if a mutation is not found in exon 28, gene study
is extended to exons 11-17 and 50-52. In 2N cases, exons
18 to 20 are sequenced, corresponding to the FVIII-binging
site. Finally, analysis of the complete coding sequence is
required in type 1 and type 3 patients, as potential muta-
tions may be spread all along VWF.12 Nonetheless, the
advent of next-generation sequencing (NGS) technology is
making molecular diagnosis of VWD by complete VWF
sequencing faster and progressively less costly,11 in partic-
ular when the new “desktop instruments” and simplified,
optimized technologies for library preparation are used.13 
Based on the results of a previous Spanish survey eluci-
dating the difficulties of diagnosing VWD,7 a multicenter,
prospective project (PCM-EVW-ES, Molecular and Clinical
Profile of von Willebrand Disease in Spain) was designed
to centrally characterize a large multicenter cohort of
VWD patients, with inclusion of NGS molecular analysis.
As described in our previous report on this project,14 this
new technology enabled us to undertake a nationwide
molecular epidemiologic study that supported a new sce-
nario for VWD diagnostics, with genetic analysis being an
indispensable first-line tool. 
Herein, we provide an in-depth description of the tech-
nical aspects of NGS-based molecular characterization of
VWF in the 556 individuals studied, complete details of
the identified variants, and a description of the results of a
genotypic-phenotypic correlation study in patients diag-
nosed with all types of VWD. 
Methods
Patients 
Molecular studies were performed on samples from 556 indi-
viduals with locally diagnosed VWD recruited in 38 Spanish hos-
pitals participating in the PCM-EVW-ES project.7,14 The inclusion
criteria were one or more of the following: 1) VWF:Ag, VWF:RCo
and/or VWF:CB ≤30% on at least two occasions regardless of the
blood group, 2) detection of multimeric abnormalities, 3) evidence
of decreased VWF:FVIIIB level in isolated FVIII deficiency, 4) pres-
ence of VWF candidate mutations, and 5) RIPA at a low ristocetin
concentration.14 Bleeding score (BS) and central laboratory pheno-
typic assessment are available in Online Supplementary Methods.
The study was performed according to the Declaration of
Helsinki, was approved by the local Research Ethics Committee,
and all participants provided written informed consent. 
VWF Access Array amplification and sequencing
We designed 61 pairs of oligonucleotides (Accession
NG_029217) capable of amplifying exons 1 to 52, intronic flanking
regions, and approximately 1300 bp of the promoter region that
were described in our previous report.14 The 48.48 Access Array
integrated fluidic circuit (IFC; Fluidigm, San Francisco, CA, USA) is
a nanofluidic chip that allows 2304 different polymerase chain
reactions (PCRs) in a final volume of 30 nL by combining 48 sam-
ples with 48 primer pairs. As 61 primer pairs are needed for total
VWF amplification, 12 multiplex PCRs were created, which
allowed 2928 reactions per chip. The Access Array was processed
following the manufacturers’ recommendations (Online
Supplementary Methods and Online Supplementary Table S1). The
outcome was a pool of all VWF amplicons from the same sample,
plus a distinctive short sequence identification label that acted as
a barcode, incorporated into each set of PCRs during the amplifi-
cation step. The final pools of up to 192 samples (four Access
Array fusion libraries) were then combined and sequenced in a
MiSeq platform (Illumina, San Diego, CA, USA; Online
Supplementary Figure S1). 
Data analysis and identification of genetic variants
Barcoded sequences were demultiplexed and analyzed individ-
ually. The NGS pipeline output, paired sequence files (FASTQ for-
mat), was used as input for analysis with the CLC Genomic
Workbench software 8.0.2 (Qiagen, Hilden, Germany). After vari-
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definitively diagnosed. Candidate mutations were identified in all patients except 13 type 1 von
Willebrand disease, yielding a high genotype-phenotype correlation. Our data reinforce the capital
importance and usefulness of genetics in von Willebrand disease diagnostics. The progressive implemen-
tation of molecular study as the first-line test for routine diagnosis of this condition will lead to increas-
ingly more personalized and effective care for this patient population. clinicaltrials.gov Identifier: 02869074.  
ant calling, the resulting files (VCF) were used as input for
VariantStudio 2.2.1 (Illumina). The result of this step is the identi-
fication of potential pathogenic variants and filtering of the poly-
morphisms described to date in the SNP (dbSNP) and 1000
Genomes databases (Figure 1). The specific analytical parameters
used are described in Online Supplementary Methods. Selected
mutations detected were validated/confirmed by Sanger sequenc-
ing.10 The nomenclature and criteria used to establish variant path-
ogenicity is also provided in Online Supplementary Methods.
In silico analysis
In silico prediction to evaluate the functional effects of putative
pathogenic variants was performed using the Alamut Visual
v.2.6.1 software (Interactive Biosoftware, Rouen, France).
Missense prediction tools included PolyPhen-2, the Sorting
Intolerant From Tolerant (SIFT), Mutation Taster, Mutation
Assessor and Provean, whereas predictive tools for synonymous
and splice site candidate mutations included GeneSplicer, Splicing
Sequences Finder (SSF), Human Splicing Finder (HSF), Neural
Network (NN) Splice and Maximum Entropy Modeling (MaxEnt).
Upstream VWF variants were localized, visualized by the
Integrative Genomics Viewer software, and compared in parallel
with datasets from the Encyclopedia of DNA Elements
(ENCODE) project to identify potential regulatory regions.15
Multiplex ligation-dependent probe amplification
(MLPA) 
VWF deletions/duplications were detected by MLPA using the
SALSA MLPA P011 and P012 VWF kits (version B2; MRC–
Holland, Amsterdam, The Netherlands), as previously
described.14,16 This method was applied to 5 patients whose geno-
type did not correlate with the phenotype 
Microsatellite analysis
A multiplex fluorescent PCR described by our group,17 compris-
ing 3 VWF intragenic tetranucleotide short tandem repeats (STR-
1, STR-2, and STR-3) and 1 dinucleotide repeat in the promoter
region (WPA) was applied to genomic DNA samples. 
Genotype-phenotype correlation
The correlation between genotype and phenotype was assessed
by experts from the central laboratories of the PCM-EVW-ES who
contrasted the results of the phenotypic test panel and the genetic
analysis on the basis of the effect and localization of mutations
and previous descriptions in the literature and/or databases.
Results
Nanofluidic VWF amplification and NGS output 
The selected VWF regions were amplified with the
Fluidigm Access Array. As each library is distinctively
labeled, up to 384 samples can be pooled and sequenced
in a single run. Fifteen Access Array and 5 MiSeq 500-
cycle runs were needed to process the 556 samples (Figure
1, Online Supplementary Results). The output quality param-
eters obtained for each run and the resulting mean values
are shown in Online Supplementary Table S2. In total, 25620
bp of VWF were sequenced in all samples, with homoge-
neous coverage for nearly all 61 amplicons (Online
Supplementary Figure S2). Regions with low or no coverage
were completed by Sanger sequencing.10 
Genotype-phenotype correlation and classification
Of the 556 individuals recruited in the PCM-EVW-ES
database, 442 had confirmed VWD based on central phe-
notype characterization. Mutation analysis by NGS was
performed in all 556 individuals, and MLPA was addition-
ally used in five (03012, 05011, 10011, 23010, 25005). Two
large deletions were identified: c.1157_5620del in patient
03012 (type 2A) due to homologous recombination
between short sequences of introns 10 and 32, and
c.(1945+1_1946-1)_(7437+1_7438-1)del in the type 3
patient, 25005 (exact breakpoints pending characteriza-
tion). Following mutation analysis, 105 were reclassified
to a different subtype, five were excluded and 43 patients
were reincluded (Figure 2) due to the presence of a candi-
date mutation in VWF: 19 type 3 VWD carriers, one type
2N VWD carrier, four type 1 VWD with borderline levels,
nine type 1H VWD, three type 2M VWD with collagen
binding mutations, and seven patients with uncertain clas-
sification. All these data, based on phenotyping and geno-
typing results, leads to a final diagnosis of VWD in 480
patients from 280 families (mean 1.7 members per family;
range 1-21) who met the criteria for inclusion in the VWF
registry (Figure 3). A total of 704 variants were identified,
237 were different, and 155 had not been described in the
VWF  European Association for Haemophilia and Allied
Disorders (EAHAD) Coagulation Factor Variant Database
compiled in the Leiden Open Variation Database (LOVD;
EAHAD-VWD-LOVD).18 The patients’ phenotypic and
molecular data were categorized according to the VWD
type and used to determine genotype-phenotype correla-
tions, which were established in 94.6% of subjects (Figure
4). Distribution of the families by VWD subtypes is
depicted in Figure 5.
Molecular epidemiology per type of VWD
VWD type 1 was diagnosed in 159 patients. In total,
216 variants were identified in 146 patients (91.8%;
Online Supplementary Table S3). Eighty-five different vari-
ants (54 undescribed in EAHAD-VWD-LOVD)18 were
scattered over VWF, being more frequent in the D3 and
D4 domains (45.9%). The five most recurrent mutations
Genetic analysis by NGS of PCM-EVW-ES
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Table 1. VWF recurrent mutations from 480 patients included in PCM-EVW-ES, classified by VWD types.
(Table 1) had been previously reported in type 1 VWD,
except for p.Leu1733Pro, with a deleterious in silico score
of 4. Patients with the p.Arg1205His, p.Pro1824His, or
p.Leu1733Pro mutations showed the lowest levels of
VWF:Ag and VWF:RCo (mean 9.1 and 7, respectively). In
30 patients subclassified as VWD 1H,14,19 the most fre-
quent mutation was p.Arg924Gln (six patients), previ-
ously described as a mutation and a polymorphism
(Online Supplementary Results). With the exception of 13
patients with no detected variant (mean VWF:Ag=31%;
range 16-48; 78% blood group O) and patient 01030 who
carried the classic p.Arg854Gln 2N mutation, a good
phenotype-genotype correlation was established in 145
patients.
Forty-two patients classified as type 3 VWD (mean
VWF:Ag=1.2%; mean BS=12.6) and 26 as carriers (mean
VWF:Ag=55%; mean BS=1.7) were present in 51 different
families (Online Supplementary Table S4). In total, 60 differ-
ent potential mutations were identified throughout VWF,
and 34 had not been previously described in EAHAD-
VWD-LOVD,18 of which 12 were mutations causing null
alleles. Genotyping was clear and correlated with the clin-
ical and laboratory data in all patients except three:
patients 05011 and 10011 with a mutation (p.Cys1946Phe
and c.5455+1G>A, respectively) in heterozygous state,
and patient 10006 with a homozygous nonsense mutation
(p.Gln2470Ter) and normal laboratory levels (pending
new analysis from a freshly obtained sample). Excluding
these three cases, the 74.4% of type 3 patients had muta-
tions leading to incontrovertible null alleles in both chro-
mosomes (Online Supplementary Figure S3A). 
Type 2A VWD was finally diagnosed in 111 patients
(detailed classification is disclosed in Online Supplementary
Results). In total, 158 variants were identified (Online
Supplementary Table S5) and most were clustered in the A1
and A2 domains (38 and 57 potential mutations, respec-
tively) encoded by exon 28. Ninety-eight patients (88%)
showed a mutation classified as 2A in EAHAD-VWD-
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Figure 1. Flowchart depicting the molecular analysis and identification of potential mutations in individuals enrolled in the study. VWF from 48 patients were simul-
taneously amplified in a 48.48 Access-Array. Alignment, variant calling and annotation of each variant identified was performed by the CLC Genomic Workbench
software. This analysis allowed selection of mutations/variants aligned against VWF (shown in gray) and elimination of those aligned against VWFP (shown in black).
Variant filtering was performed by the Variant Studio software. *MAF<0.01 for all variants except three (p.Arg854Gln, p.Arg924Gln, p.Pro2063Ser). VWF: von
Willebrand factor gene; VWFP: von Willebrand factor pseudogene; dbSNP: dbSNP database; 1000G: 1000 Genomes Project; ExAC: Exome Aggregation Consortium;
MAF: minor allele frequency; NGS: next-generation sequencing. 
LOVD,18 and the remaining 13 patients had novel candi-
date mutations in one of the 2A-associated domains (D2,
D3, A1, A2, and CK). Hence, an unflawed phenotype-
genotype correlation was found in all except four patients:
patient 42010, who showed a previously described 2A
mutation (p.Arg1527Gln)20 with healthy compatible
VWF:Ag and VWF:RCo levels (pending  new analysis of a
freshly obtained sample), patient 03012, who had a large
in-frame deletion affecting residue 386-1873 (domains D2-
A3), although this type of mutation seldom explains a 2A
phenotype21 and additional studies are needed to investi-
gate the molecular origin, and patients 02071 and 02072,
who had a nearly normal multimeric pattern and
VWF:RCo/VWF:Ag>0.7 due to the heterozygous mis-
sense mutations, p.Arg976Cys (described as 2A/IIE)22 and
p.Pro2063Ser. 
Thirty-four patients were classified as type 2A/2M
VWD (Figure 3 and Online Supplementary Table S6).
Remarkably, all families save three presented one of the
widely described p.Arg1315Cys and p.Arg1374Cys muta-
tions, located in the A1 domain.23,24 These two controver-
sial mutations were difficult to classify in the light of pre-
vious reports and were assigned to 2A/2M, mainly
because of their abnormal VWF multimers in medium-res-
olution gels.25 The new p.Arg763Ser potential mutation,
involved in proteolytic processing of the VWF precursor,
was found in heterozygous state in two families with
symptomatic patients (BS >4), a smeary multimeric pat-
tern, and VWF:FVIIIB <0.7. Of note, mutations in the
same amino acid (p.Arg763Gly) have been described in
type 2N, but heterozygous patients for this mutation were
asymptomatic and classified as 2N carriers.26,27 The remain-
ing family showed p.Cys2491Arg, described as type 3,
which involves loss of a cysteine essential for VWF secre-
tion, but these patients were classified as 2A/2M based on
their multimeric pattern. Taking these data together, a
complete genotype-phenotype correlation could be estab-
lished for all 2A/2M patients. 
Thirty-five patients were diagnosed as having type 2B
VWD (detailed classification is disclosed in Online
Supplementary Results and Online Supplementary Table S7).
Interestingly, among the 16 residues associated with type
2B VWD, one out of five of them—p.Pro1266, p.Arg1306,
p.Arg1308, p.Val1316 or p.Pro1337—was found to be
affected. A good phenotype-genotype correlation could be
established for all patients, as most showed a loss of high-
molecular-weight multimers and discordance between
VWF:Ag and VWF:RCo levels (mean ratio=0.51; range
0.19-1.1) and a classical type 2B mutation. A normal mul-
timeric pattern and VWF:RCo/VWF:Ag>0.7 were
observed in only two families. As expected, the classical
p.Pro1266Leu and p.Pro1266Gln molecular defects were
found, both being responsible for type 2B Malmö/New
York VWD.28,29
Thirty-nine patients were classified as type 2M VWD
(Online Supplementary Table S8). Twenty-one different mis-
sense variants were found, ten undescribed in EAHAD-
VWD-LOVD.18 Of interest, in eight patients with a high
Genetic analysis by NGS of PCM-EVW-ES
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Figure 2. Classification of VWD patients based on central phenotypic diagnosis and final assignment according to the genotype-phenotype correlation. The dataset
highlights the number of patients reincluded or reclassified after molecular study, from the initial classification based on central phenotypic results (shown in black)
to a definite, refined classification based on molecular data analysis together with phenotypic results (shown in gray). *Patients diagnosed initially as type 1 VWD
and reclassified to type 2M VWD due to the presence of collagen binding mutations. †Patient with uncertain classification reclassified to type 3 VWD due to the pres-
ence of nonsense mutation in homozygous state. This is a discrepant case since laboratory levels do not correlate and it is pending a new analysis from a freshly
obtained sample. Out: number of patients removed from this subtype; To: final definite classification; In: number of patients reclassified to this subtype; From: pre-
vious phenotypic classification; UC: uncertain classification; AVWS: acquired von Willebrand Syndrome. 
VWF:RCo/VWF:Ag ratio, collagen-binding mutations
were  identified: p.Arg1399His, p.Ser1731Thr, and the
novel p.Arg1395Trp.30 All patients showed mutations in
the 2M-associated domains A1 and A3, with the excep-
tion of three patients who had mutations in other
domains, and patient 27022 (carrying p.Ser1731Thr, a col-
lagen I/III-binding mutation, but with VWF:CB=41), con-
sidered to have a discrepant genotype-phenotype correla-
tion.
A perfect phenotype-genotype correlation was estab-
lished in all type 2N VWD patients (Online Supplementary
Table S9). Two classical 2N mutations were present in all
patients: p.Arg816Trp in exon 19, and p.Arg854Gln in
exon 20, the latter seen in 75% of cases.  Different combi-
nations of mutation types were found (Online
Supplementary Figure S3B): five patients homozygous for a
2N mutation, and four patients compound heterozygous
in trans for p.Arg854Gln and a nonsense mutation or
p.Gln895His, reported to cause low VWF expression at the
messenger ribonucleic acid (mRNA) level.31 
In 14 patients the classification was uncertain (Online
Supplementary Table S10) because phenotyping or geno-
typing data were insufficient or inconclusive to indu-
bitably establish the classification. This occurred in eight
patients with novel variants of unknown significance
(VUS) who had a normal or nearly normal phenotype, and
six patients with an abnormal multimeric pattern,
VWF:RCo/VWF:Ag <0.7, and a novel candidate mutation.
In these cases, it was difficult to distinguish between 2A
or 2B VWD since RIPA assay was not assessed. 
Molecular epidemiology per type of mutation
A total of 237 different variants were identified in our
cohort (Online Supplementary Figure S4A) and a potential
ancestral origin was established in 19 of them. All vari-
ants, classified by type, are listed in Online Supplementary
Tables S11-S17. 
In total, 119 different missense candidate mutations
were identified, scattered over all domains of VWF (33 of
52 exons). Sixty were not included in EAHAD-VWD-
LOVD18 (Online Supplementary Figure S4B) and the mean in
silico score in this group was 3.50 (standard deviation (SD)
1.60). The remaining 59 mutations, previously found in
VWD patients, had a similar score of 3.54 (SD 1.62).
Twenty-three different nonsense mutations were found,
12 unrecorded in EAHAD-VWD-LOVD.18 As expected,
nonsense mutations predominantly occurred in type 3
VWD (41 patients). However, we also found this type of
mutation in nine type 1 VWD patients, two type 2N, and
one type 2A. Of particular note, several mutations were
detected in different VWD types. For example,
p.Arg324Ter was found in types 3 and 2N, and
p.Gln840Ter, p.Gln1311Ter and p.Gln2470Ter were found
in types 1 and 3. Five new inframe candidate mutations
(two insertions and three deletions) causing different
types of VWD were identified. Thirteen potential splicing
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Figure 3. Summary of the final diagnosis of patients in terms VWD type. On the basis of phenotype data, 98 of the 556 recruited individuals did not meet any inclu-
sion criteria and were initially excluded. Following the molecular analysis, 43 of these patients were reincluded due to the presence of a candidate mutation in VWF.
The remaining 55 patients did not meet any inclusion criteria. Moreover, molecular analysis prompted the exclusion of 21 additional individuals: eight HA patients,
five HA carriers, and eight patients finally diagnosed as AVWS and confirmed by the absence of mutations in VWF or GP1BA. Of note, 280 families were finally includ-
ed (shown in black) and nine of them had members with different VWD types. In those particular cases, the family may be counted more than once; that is, within
each VWD type where a family member was classified. VWD: von Willebrand disease.
mutations were found, eight undescribed in EAHAD-
VWD-LOVD.18 Their deleterious effect was assessed by
five in silico tools: 11 had a predicted effect on splicing, but
two of them, those farthest from the exon to be precise,
were predicted to have no significant impact on splicing.
Ten different upstream variants were found in 20 families
with all types of VWD. Only c.-1896C>T and c.-1873A>G
have been previously described,32,33 and these were found
in type 2A/2M and 2M, respectively. According to their
genomic localization, all but the three most upstream (c.-
3151T>G, c.-2692C>T, c.-2627C>T) were mapped in
regions with well-defined or potential regulatory ele-
ments. Sixteen synonymous and 51 intronic variants were
identified, but only 5 and 3, respectively, were recorded in
EAHAD-VWD-LOVD.18 Although it is difficult to demon-
strate, any nucleotide change can be considered a poten-
tial candidate to alter splicing, especially when an intronic
or synonymous variant appears next to an intron/exon
junction.34,35 
Discussion
This report describes the molecular study of VWF in the
largest prospective multicenter cohort of VWD patients to
date, made possible by the development and successful
application of NGS technology. The method presented
herein has also been used in a smaller Portuguese cohort,
with a similar diagnostic yield.16 Heretofore, VWF genetic
analysis in large cohorts has been performed by Sanger
sequencing.32,33,36,37 In the study herein, considerable time
and cost savings were attained by combining two high-
throughput technologies, nanofluidics and NGS. The
hands-on time and instrument run times for sequencing
the 556 patients initially enrolled can be measured in days
or weeks rather than months, whereas the cost per sample
in our setting was less than $70, 10-fold lower than Sanger
sequencing. 
The method developed for VWF sequencing is fast and
cost-effective for large patient groups; hence, it would
seem inappropriate for routine diagnostic laboratories that
accumulate small numbers of patients. Nonetheless, NGS
can also be applied to individual samples by using the
gene panel approach.38 In our opinion, the debate about
whether genetic analysis is appropriate for all types of
VWD12 will become obsolete in the light of this new tech-
nological scenario. It is reasonable to believe that NGS will
be progressively incorporated in routine VWD diagnos-
tics.
Centralized comprehensive population studies,
although logistically complex, would be the best way to
obtain a clear picture of this disease and investigate con-
nections between the multifactorial parameters that influ-
ence the diagnosis and etiology.12 In this study, 704 vari-
ants (237 unique) were compiled (Online Supplementary
Tables S11-S17), whereas the total number of entries in
EAHAD-VWD-LOVD18 is about 1,200 (708 unique), an
indication of the effectiveness of this approach for the
genetic study of large cohorts. In contrast to other studies,
the present project included patients with all VWD types
and used an identical protocol (whole VWF sequencing)
for their genetic analysis. The mutation detection rate was
high compared with that of previous studies, being close
to 100% in some VWD types (Figure 3). Candidate muta-
tions were identified in 91.8% of type 1 individuals versus
the 65-82% reported in previous studies,32,33,36,39 a result
that may be related to the limiting recruitment of patients
with VWF level <30%. 
With regard to the most recurrent mutations identified
(Table 1), the Vicenza mutation (p.Arg1205His) proved to
be the most common in our type 1 patients, in contrast to
previous studies where p.Tyr1584Cys was prevalent.32,33,40
In type 3 VWD, p.Gln1311Ter41 was one of the most fre-
quent mutations detected, as was also seen in the
Portuguese population study,16 whereas in patients from
northern Europe, p.Arg2535Ter is predominant. As to type
2, the most common mutations found were similar to
those reported in previous cohort studies.
Perhaps more important than elucidation of the molec-
ular epidemiology of VWD were the data obtained by
NGS, that can resolve many of the drawbacks and limita-
tions of phenotyping.  First, molecular characterization of
VWD patients enables accurate classification: 27.5% of
our patients (153/556) were re-diagnosed after the initial
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Figure 4. Schematic representation of phenotype/genotype correlations by VWD type. The correlation between genotype and phenotype in each patient was based
on the concordance between the results of the phenotypic test panel and the results of the genetic analysis.
phenotypic study, 43 reincluded, five patients excluded,
and 105 reclassified. Of note, 68 patients with uncertain
classification were definitively classified by NGS, as in the
case of 25 type 2A patients and ten type 2B missing previ-
ous RIPA data. Furthermore, four patients whose pheno-
type pointed to VWD type 1 were found to have 2B
Malmö or collagen-binding mutations (Figure 2), the latter
being undetectable by standard laboratory tests unless
specific binding capacity for collagen types III, IV and VI is
performed. Accurate classification is particularly relevant
for genetic counseling and detection of carriers in VWD
types with autosomal recessive inheritance. We identified
11 asymptomatic carriers 2N and 26 type 3 with border-
line plasmatic levels, who would likely have been exclud-
ed if the diagnosis had been based only on clinical and lab-
oratory data. Knowledge of the molecular defect also led
to diagnostic reassessment of some type 1 patients who
could be considered carriers of type 3 mutations (e.g.,
patient 06024 with the p.Arg2434Ter mutation).
Second, genetic study showed that 37.5% of patients in
our cohort had more than one variation, a finding essential
to unravelling the potential contribution of different vari-
ants to the final phenotype. The situation of two 2M
patients is paradigmatic in this regard: 44003, with the
p.Gly1415Asp mutation and very low FVIII levels (11%)
due to a 2N mutation in heterozygous state, and 03024,
who had the p.Val1409Phe plus the p.Arg1399His muta-
tion in trans, which explains the reduction in collagen-
binding affinity in this patient.
Third, genetic analysis in large cohorts could shed light
on differentiating a variant previously described as a
mutation or polymorphism, such as p.Pro1162Leu caused
by the c.3485C>T substitution, described as a polymor-
phism in African Americans.42 Conversely, in our cohort
p.Pro1162Leu was caused by c.3485_3486delinsTG (pre-
dicted by in silico analysis with effect on splicing), leading
to type 3 phenotype in homozygous state.16 These data
suggest that different variants resulting in identical amino
acid changes may have different consequences at the tran-
scriptional level. Additionally, regarding the controversial
p.Pro2063Ser variant, a recent report by Kasatkar et al.43
has provided evidence that p.Pro2063Ser in homozygous
state causes type 3 VWD. Hence, five patients in our
cohort heterozygous for p.Pro2063Ser were classified as
type 3 carriers. 
Fourth, genetic studies can offer valuable data regarding
the molecular pathophysiological mechanisms responsible
for the symptoms observed, such as defects in the struc-
ture, intracellular transport, or secretion of VWF. The loca-
tion of new mutations in certain domains or specific
amino acids helps to predict their potential effect, particu-
larly if previous in vitro studies are performed. Examples of
this are the new mutations p.Arg273Pro, located in the
propeptide and related with formation of disulphide-
linked multimers,44 p.Arg763Ser, located in the VWF
propeptide cleavage site,26 and p.Arg1395Trp, which
affects an essential amino acid for collagen IV binding.30
In addition, although this approach cannot resolve some
discrepant cases and those in which no candidate muta-
tion is found (3.1% of our cohort), exome and genome
studies by NGS are useful to identify modifying mutations
in other genes45 and reveal structural variations unde-
tectable by MLPA.46 It is also important to point out that
the technique has provided molecular data for more than
100 cSNPs described in VWF, which will be further ana-
lyzed to determine their potential influence on VWF:Ag,
FVIII:C and bleeding in our cohort, as has been done in
some healthy populations.42,47 If some of these SNPs are
found to contribute to the disease, they could be redefined
as hemorrhagic risk polymorphisms (similar to the throm-
botic risk polymorphisms).
The final obstacle to an accurate diagnosis is the uncer-
tain pathogenicity of novel variations. In silico analysis is
considered a suitable supporting tool for genetic diagnosis,
and we analyzed all variants using algorithms recom-
mended in specialized guidelines.48 However, the predic-
tive capacity of these programs remains modest: some
well-established deleterious mutations have a lower over-
all score (e.g., p.Leu1580Pro, score=2) than some polymor-
phisms (e.g., p.Cys325Phe, predicted to be deleterious by
N. Borràs et al.
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Figure 5. Classification of the 280 families included according to VWD type. Numbers in parentheses refer to the total of families included in each VWD type. Of
note, nine of the 280 families included in the PCM-EVW-ES presented a mixed phenotype (families in which some members had different VWD subtypes). UC: patients
with an uncertain classification. 
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SIFT and PolyPhen).49 Therefore, in order to unequivocally
determine the potential deleterious effect of new variants,
in vitro functional studies remain essential.50
Herein, we present the largest prospective study to date
of a cohort of VWD including an exhaustive description of
their molecular epidemiology. This data will improve
knowledge about the molecular mechanisms that con-
tribute to the complexity of disease diagnosis and will
help to elucidate the relationship between bleeding
parameters and the patients’ laboratory and genetic pro-
files. The approach used implies a change in the diagnos-
tic paradigm of VWD, which is also occurring in other
genetic diseases. The cost reduction and simplification of
genetic analysis by NGS will likely lead to the use of
molecular study as an additional first-line routine diagnos-
tic test, with the ultimate aim of providing more person-
alized and effective care for this patient population.
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